Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 30;6:43. doi: 10.1186/s40425-018-0352-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 2 — Case B. FDG-avid adenopathy before and after RT with target volume outlined in red and untreated disease outlined in blue. Left (Panel a): Coronal pre-RT PET/CT demonstrating mediastinal FDG-avid adenopathy in the mediastinum and bilateral hila (top) and upper abdomen (bottom); not pictured: supraclavicular adenopathy. Right (Panel b): Coronal PET/CT at 12 months after RT demonstrating radiographic response in the mediastinum and bilateral hila (top) and radiographic response in the upper abdomen (bottom). Panel c: Timeline of therapy and disease status, with A and B corresponding to time points depicted in Panel a and b above. c1 = cycle 1 of pembrolizumab. RT = radiation therapy. PET/CT = positron emission tomography/computed tomography. FDG = fludeoxyglucose